| VIEW POINT |
|
| Year : 2019 | Volume
: 22
| Issue : 2 | Page : 131-136 |
|
|
Can we treat secondary progressive multiple sclerosis now?
Rohit Bhatia, Nishita Singh
Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
Correspondence Address:
Dr. Rohit Bhatia
Department of Neurology, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi - 110 029
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/aian.AIAN_345_18
|
|
|
Secondary progressive multiple sclerosis (SPMS) is characterized by progressive accumulation of disability without intermittent recovery. Treatment of these patients is challenging due to limited understanding of pathogenesis and fewer therapeutic options. This article summarizes difficulties in defining and conducting trials in SPMS, review major clinical trials on therapies approved and unapproved in SPMS and lastly, therapies in pipeline for use in SPMS.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
